Study Ties Inherited Gene Variants to Distinct Cancer Risk Patterns

Patient registries have become one of the more useful research tools in hereditary cancer genetics, precisely because so much about how inherited variants actually behave in the body is still being worked out gene by gene. The PROMPT registry — Prospective Registry Of MultiPlex Testing — is an online research registry for people who have undergone multiplex gene panel testing for cancer risk. Participants contribute personal and family health history, with the goal of building a larger picture of lesser-known cancer risks tied to genes that individual studies are often too small to characterize well on their own. PROMPT also collaborates with GenomeConnect, a separate registry that lets participants share genetic results and connect with others who carry similar variants.

That kind of aggregated data is starting to intersect with laboratory research on how inherited variants actually interact with the mutations a tumor acquires later on. Researchers at Washington University School of Medicine, publishing in the journal Cell, analyzed inherited cancer mutations in blood samples from more than 1,000 cancer patients and found that these germline variants can produce malfunctioning proteins capable of predisposing someone to cancer at different life stages. The same research suggested that patients with higher “polygenic risk scores” — a combined measure of all inherited mutations a person carries, rather than looking at any single gene in isolation — may face elevated risk for more aggressive cancers, including glioblastoma, pancreatic cancer, and aggressive forms of lung cancer.

Research from the Brugge Lab found that a heterozygous state — carrying just one mutated copy — of the BRCA1 gene can “prime” cells for cancer initiation independently of the complete loss of BRCA1, offering a new angle on early intervention.

That finding matters because most clinical thinking about BRCA1 has historically focused on what happens once both copies of the gene are lost or disabled. Evidence that a single mutated copy can already begin nudging cells toward cancer initiation — before the “second hit” that classical models describe — suggests there may be more to learn about the biology of carriers long before a tumor is detectable.

Registries designed around long-term follow-up are also demonstrating direct clinical value, not just research value. The Dutch Hereditary Cancer Registry, which identifies families with hereditary cancer and enrolls them in structured colonoscopic surveillance programs, has been associated with a substantial decrease in colorectal cancer mortality among enrolled families — attributed specifically to the registry’s model of ongoing registration paired with continued surveillance rather than a one-time test result. The Inherited Cancer Registry (ICARE) is pursuing a related but distinct goal, focusing research on inherited cancer predisposition in populations affected by broader cancer health disparities.

For people who have already had multi-gene panel testing, registries like PROMPT represent a low-friction way to contribute to exactly the kind of long-term, real-world data that individual clinical trials struggle to gather — particularly for the many genes on modern panels where cancer risk is still only partially understood. Participation doesn’t replace guidance from a genetic counselor, but it does help build the evidence base that future guideline updates will eventually draw on.